Leveraging Real‑World Evidence to Fulfill Post‑Approval Regulatory Commitments

Understanding the Role of RWE Post‑Approval

After a drug or biologic gains regulatory approval, its journey is far from over. Regulators often impose post‑approval commitments—studies designed to confirm long-term safety, effectiveness, and risk mitigation strategies in the real-world population. While randomized controlled trials (RCTs) have long been the gold standard, they can be expensive, time-consuming, and less reflective of real-world conditions.

Real‑World Evidence (RWE) offers a powerful complement to RCTs. Derived from Real‑World Data (RWD) such as electronic health records (EHRs), insurance claims, patient registries, and even digital health apps, RWE allows regulators and sponsors to monitor products in diverse, real-life settings. Increasingly, RWE is being used to satisfy post-approval requirements under frameworks from the FDA, EMA, PMDA, and Health Canada.

Types of Post‑Approval Commitments Supported by RWE

RWE can be used to fulfill several types of post‑marketing regulatory obligations, including:

• Post-Marketing Requirements (PMRs) mandated by the FDA for accelerated approvals or unresolved safety issues
• Post-Marketing Commitments (PMCs) agreed upon by sponsors to provide additional evidence after approval
• Risk Evaluation and Mitigation Strategies (REMS) with elements to assure safe use, requiring real-world monitoring
• Post-Authorization Safety Studies (PASS) and Post-Authorization Efficacy Studies (PAES) in the EU

These studies often require long-term observation across large patient populations, making RWE-based methodologies particularly attractive.

Regulatory Acceptance of RWE: A Global Overview

The FDA’s RWE Framework under the 21st Century Cures Act outlines scenarios where RWE can support regulatory decision-making, including fulfilling PMRs. The agency has released guidance on using EHRs and medical claims data, and the PDUFA VII commitments (2023–2027) further elevate RWE’s role.

In the European Union, EMA’s DARWIN EU platform is centralizing access to RWD for regulatory use. Japan’s PMDA and Health Canada are similarly piloting regulatory-grade RWE integration in post-market surveillance.

Examples of RWE Use in Post‑Approval Settings

Several landmark cases illustrate the feasibility and value of RWE in fulfilling regulatory obligations:

• Blincyto (blinatumomab): Accelerated FDA approval was followed by confirmatory safety and effectiveness assessments via real-world registry data for relapsed/refractory acute lymphoblastic leukemia.
• Covid-19 Vaccines: Post-market surveillance using EHR and claims data across multiple countries helped confirm safety in pregnancy, children, and patients with comorbidities.
• Oncology Observational Studies: Flatiron Health’s real-world datasets have supported post-approval evaluations of checkpoint inhibitors and CAR-T therapies.

Study Designs for RWE‑Based Commitments

Unlike RCTs, RWE studies typically use observational designs, such as:

• Retrospective Cohort Studies: Leverage historical patient data to assess long-term outcomes
• Prospective Registries: Track patients in real-time under routine clinical practice
• External Control Arms: Use RWD as a comparator group when an RCT arm is not feasible
• Pragmatic Clinical Trials: Blend trial structure with real-world care delivery models

These methods are particularly suited to rare diseases, pediatric populations, or patients excluded from trials—addressing diversity gaps in initial evidence packages.

Design Considerations and Methodological Challenges

To ensure RWE meets regulatory standards, sponsors must address several key challenges:

• Data Completeness and Accuracy: Missing or miscoded entries in EHRs and claims can distort outcomes.
• Selection Bias: Patients in real-world cohorts differ significantly from RCT participants.
• Confounding Variables: Lack of randomization means confounders must be controlled using statistical models.
• Endpoint Validity: Outcomes should align with pre-approved definitions and data availability.
• Regulatory Dialogue: Early interaction with agencies helps determine if RWE design meets acceptability thresholds.

Data Sources for RWE Generation

Common data types used to construct RWE studies include:

Best Practices for Sponsors Using RWE for Commitments

• Engage with the FDA/EMA via Type B/C meetings early to confirm study design acceptability
• Validate data sources through feasibility studies and pilot testing
• Use propensity score matching, regression adjustment, or instrumental variable methods for confounding control
• Implement a statistical analysis plan (SAP) and pre-specify outcomes
• Utilize eCTD Module 5 format to submit RWE study results

Case Study: RWE for Expanded Indication Approval

A respiratory drug approved for adults was considered for adolescent asthma treatment. Instead of initiating a full-scale trial, the sponsor aggregated RWE from multiple pediatric pulmonology centers across the U.S. and EU. Outcomes, including exacerbation frequency and steroid reduction, were compared to existing adult efficacy data. With additional literature bridging and population matching, EMA accepted the submission under a Type II variation supported primarily by RWE.

Future Outlook: Global Convergence on RWE Use

As agencies collaborate on data standards and evidence frameworks, we may see mutual recognition of RWE studies across regions. Initiatives like ICH E19 and CIOMS RWE guidelines aim to harmonize definitions, quality controls, and endpoint criteria.

Sponsors will benefit from investing in internal RWE infrastructure, including biostatistical expertise, data partnerships, and systems for RWE protocol governance.

Conclusion: RWE Is a Pillar of Post‑Approval Regulatory Strategy

Real‑World Evidence has emerged as a credible, regulator-endorsed strategy to fulfill post‑approval obligations. Whether used to support REMS, confirm safety profiles, or expand patient populations, RWE enables faster, more relevant, and often more cost-effective compliance.

As global regulatory bodies align, RWE will continue to reduce the time and burden of traditional trials while upholding safety and public health. For sponsors, the time to operationalize RWE as a formal component of post-approval strategy is now.

How to Link EHRs and Claims Data to Generate Real-World Evidence

In real-world evidence (RWE) research, integrating data from different sources is essential for a comprehensive understanding of patient journeys. One powerful method is linking Electronic Health Records (EHRs) with administrative claims data. This fusion offers a complete view of clinical encounters, treatments, outcomes, and healthcare utilization — crucial for pharmacoeconomic evaluations, comparative effectiveness studies, and regulatory decision-making.

This tutorial provides a structured guide to linking EHRs and claims data in pharma research. It outlines methods, challenges, regulatory compliance, and validation strategies to ensure high-quality evidence generation.

Why Link EHRs and Claims Data?

Each data source offers complementary strengths:

• EHRs: Rich in clinical details like lab results, vitals, diagnosis codes, and treatment protocols.
• Claims: Complete data on billing, procedures performed, medication dispensing, and cost metrics.

Linking these datasets allows for:

• Improved accuracy of exposure and outcome definitions
• Comprehensive longitudinal tracking of patients
• Enhanced generalizability of RWE studies
• Better analysis of healthcare resource utilization (HRU)

As GMP compliance emphasizes data integrity, linking must preserve accuracy, traceability, and confidentiality.

Step-by-Step Process of Data Linkage:

Step 1: Define Study Objectives and Data Requirements

Before linking, clarify the purpose of combining datasets. Are you measuring treatment outcomes, adherence, or adverse events? Based on objectives, determine which data elements are needed — diagnoses, labs, prescriptions, hospitalizations, or costs.

Step 2: Choose the Type of Linkage

Two primary approaches are used for data linkage:

1. Deterministic Linkage: Uses unique identifiers (e.g., patient ID, social security number) available in both datasets. High precision but often restricted due to privacy laws.
2. Probabilistic Linkage: Matches records using common variables like name, date of birth, gender, zip code. Allows linkage in absence of unique IDs but requires algorithm validation.

Ensure that SOP documentation exists for each chosen linkage method.

Key Variables for Matching:

Use combinations of the following to improve matching accuracy:

• Full name or encoded name
• Date of birth
• Sex
• Geographical region (zip code, state)
• Health plan ID or medical record number

In probabilistic methods, assign weights to each match variable. Use thresholds to classify records as matches, non-matches, or possible matches requiring manual review.

Privacy and Data Security Considerations:

Linking datasets raises serious data protection concerns. According to USFDA and pharma regulatory norms:

• Use de-identified or limited datasets unless explicit consent is available.
• Establish Data Use Agreements (DUAs) and Business Associate Agreements (BAAs).
• Encrypt identifiers during linkage.
• Use secure linkage environments or third-party honest brokers.

All linkage procedures must comply with HIPAA, GDPR, or local privacy laws depending on data geography.

Data Harmonization and Cleaning:

Once linked, datasets must be harmonized to a common structure. Normalize variable formats, coding systems (ICD-10, CPT, LOINC), and timestamps. Address discrepancies in units, value ranges, and terminology.

Best practices include:

• Code mapping using crosswalks or dictionaries
• Unit conversions for labs and vitals
• Consolidation of visit-level and claim-level records
• Outlier and missing value imputation

Validate with internal controls and follow stability studies best practices to ensure data consistency over time.

Validation of Linked Datasets:

Evaluate linkage quality through:

• Match rate: Proportion of successfully linked records
• Precision: Accuracy of matches compared to a gold standard
• Recall: Proportion of all possible matches correctly identified
• Manual audits: Review a sample for verification

Document all processes in a linkage protocol and ensure reproducibility in case of audits or publication requirements.

Applications of Linked EHR-Claims Data in Pharma:

• Drug Safety Surveillance: Detect rare adverse events across larger populations
• Comparative Effectiveness Research (CER): Evaluate outcomes across therapies
• Medication Adherence Studies: Use claims refill data with clinical measures
• Cost-Effectiveness Analyses: Combine utilization and clinical response data
• Post-Marketing Authorization Studies: Meet regulatory RWE requirements

These applications align with the increasing demand for RWE in regulatory submissions and reimbursement decisions.

Common Challenges and Solutions:

Challenge 1: Incomplete or Mismatched Data

Solution: Use fuzzy matching algorithms and imputation. Flag unmatched records for sensitivity analysis.

Challenge 2: Privacy Restrictions

Solution: Leverage limited datasets or honest broker models for secure linkage.

Challenge 3: Time Misalignment

Solution: Synchronize timestamps across datasets using standardized date windows and episode definitions.

Challenge 4: Variability in Coding Systems

Solution: Use unified vocabularies (SNOMED CT, RxNorm) and normalize data to a common data model (e.g., OMOP CDM).

Best Practices Checklist:

• Clearly define linkage objectives and variables
• Choose appropriate deterministic or probabilistic methods
• Ensure legal and ethical compliance with HIPAA and GDPR
• Perform quality checks and manual validation
• Harmonize variables post-linkage
• Maintain full documentation and audit trails

Conclusion: Unlocking Value Through Data Linkage

Linking EHR and claims data is a transformative strategy for pharma researchers aiming to build robust, comprehensive real-world evidence. It combines the depth of clinical information with the breadth of healthcare utilization, allowing for more accurate and reliable analysis of medical interventions.

By following structured linkage methodologies and maintaining validation master plans, pharma professionals can meet both scientific and regulatory expectations in their RWE studies.